{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:55:09Z","timestamp":1794268509693,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014660","name":"Society for the Study of Addiction","doi-asserted-by":"crossref","award":["Griffith Edwards Academic Fellowship"],"award-info":[{"award-number":["Griffith Edwards Academic Fellowship"]}],"id":[{"id":"10.13039\/100014660","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153342"],"award-info":[{"award-number":["PJT-153342"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UKRI Future Leaders Fellowship","award":["MR\/Y017560\/1"],"award-info":[{"award-number":["MR\/Y017560\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Population data on cannabis use\u2014beyond prevalence and frequency of use\u2014in the UK is lacking, yet needed to inform harm reduction messaging about cannabis. This study examined (a) recreational and medical cannabis use; (b) cannabis product use; (c) cannabis risk perceptions via three different routes of administration; (d) how product use and risk perceptions vary by reasons for use and higher risk use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were from UK respondents of the 2023 International Cannabis Policy Study. National surveys included 3444 UK residents and 1590 people who consumed cannabis in the past year aged 16\u201365. Weighted logistic regression examined associations between product use, risk perceptions and reasons for use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>50.9% of people who reported consuming cannabis reported doing so for recreational reasons only, 12.1% for medical reasons only, and 31.3% for both reasons. Dried flower was the most consumed product both in the past year (68%). Edibles (38.9%), vape oils (30.5%) and hash (27.5%) were the next commonly consumed products. People who consumed cannabis in the past year that screened positive for higher risk use were more likely to report consuming non-flower products (AOR 3.15, 95% CI 2.17, 4.58) than only dried flower. There were a higher percentage of respondents\u2014regardless of whether they consumed cannabis or not\u2014that reported perceiving consuming edibles daily as low or very low risk than smoking or vaping cannabis daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is diversity in the UK cannabis market in terms of the reasons for use and the products consumed. Understanding product use beyond just \u2018cannabis\u2019 and risk perceptions across different routes of administration is important for informing harm reduction messaging and evaluating policies to minimise harm and maximise benefit from both recreational and medical cannabis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01456-4","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:14:05Z","timestamp":1777050845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cannabis products and risk perceptions among people who consume and do not consume cannabis in the UK: findings from the International Cannabis Policy Study"],"prefix":"10.1186","volume":"23","author":[{"given":"Elle","family":"Wadsworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"1456_CR1","unstructured":"Office for National Statistics. Drug misuse in England and Wales: year ending March 2024. 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/articles\/drugmisuseinenglandandwales\/yearendingmarch2024. Accessed 3 July 2025."},{"issue":"48","key":"1456_CR2","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1017\/S0033291717003877","volume":"2018","author":"TP Freeman","year":"2018","unstructured":"Freeman TP, van der Pol P, Kuijpers W, Wisselink J, Das RK, Rigter S, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med. 2018;2018(48):2346\u201352.","journal-title":"Psychol Med"},{"issue":"5","key":"1456_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/add.15253","volume":"116","author":"TP Freeman","year":"2021","unstructured":"Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000\u201310. https:\/\/doi.org\/10.1111\/add.15253.","journal-title":"Addiction"},{"key":"1456_CR4","volume":"10","author":"J Manthey","year":"2021","unstructured":"Manthey J, Freeman TP, Kilian C, Lopez-Pelayo H, Rehm J. Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. Lancet Reg Health. 2021;10:100227.","journal-title":"Lancet Reg Health"},{"issue":"1","key":"1456_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3109\/09687637.2015.1090398","volume":"23","author":"M Monaghan","year":"2015","unstructured":"Monaghan M, Hamilton I, Lloyd C, Paton K. Cannabis matters? treatment responses to increasing cannabis presentations in addiction services in England. Drugs Educ Prev Policy. 2015;23(1):54\u201361.","journal-title":"Drugs Educ Prev Policy"},{"key":"1456_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2016.00104","volume":"7","author":"C Hindocha","year":"2016","unstructured":"Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR. No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry. 2016;7:104.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1456_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/dta.2368","volume":"10","author":"DJ Potter","year":"2018","unstructured":"Potter DJ, Hammond K, Tuffnell S, Walker C, Di Forti M. Potency of \u03949 -tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Test Anal. 2018;10(4):628\u201335. https:\/\/doi.org\/10.1002\/dta.2368.","journal-title":"Drug Test Anal"},{"key":"1456_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102658","volume":"76","author":"S Goodman","year":"2020","unstructured":"Goodman S, Wadsworth E, Leos-Toro C, Hammond D. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy. 2020;76:102658.","journal-title":"Int J Drug Policy"},{"key":"1456_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103716","volume":"105","author":"D Hammond","year":"2022","unstructured":"Hammond D, Goodman S, Wadsworth E, Freeman TP, Kilmer B, Schauer G, et al. Trends in the use of cannabis products in Canada and the USA, 2018\u20132020: findings from the International Cannabis Policy Study. Int J Drug Policy. 2022;105:103716.","journal-title":"Int J Drug Policy"},{"key":"1456_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108505","volume":"219","author":"D Hammond","year":"2021","unstructured":"Hammond D, Wadsworth E, Reid JL, Burkhalter R. Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019. Drug Alcohol Depend. 2021;219:108505.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1456_CR11","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/s41598-018-22755-2","volume":"8","author":"N Jikomes","year":"2018","unstructured":"Jikomes N, Zoorob M. The cannabinoid content of legal cannabis in Washington state varies systematically across testing facilities and popular consumer products. Sci Rep. 2018;8(1):4519.","journal-title":"Sci Rep"},{"issue":"3","key":"1456_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","volume":"2","author":"M Di Forti","year":"2015","unstructured":"Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M. Proportion of patients in South London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1456_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","volume":"6","author":"M Di Forti","year":"2019","unstructured":"Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u201336.","journal-title":"Lancet Psychiatry"},{"issue":"15","key":"1456_CR14","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1017\/S0033291715001178","volume":"45","author":"TP Freeman","year":"2015","unstructured":"Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181\u20139.","journal-title":"Psychol Med"},{"key":"1456_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1205","volume":"350","author":"W Hall","year":"2015","unstructured":"Hall W, Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. BMJ. 2015;350:h1205.","journal-title":"BMJ"},{"issue":"9","key":"1456_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","volume":"9","author":"K Petrilli","year":"2022","unstructured":"Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry. 2022;9(9):736\u201350.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"1456_CR17","first-page":"879","volume":"371","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;371(9):879.","journal-title":"N Engl J Med"},{"issue":"10","key":"1456_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/jamapsychiatry.2020.1035","volume":"77","author":"LA Hines","year":"2020","unstructured":"Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, et al. Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat. 2020;77(10):1044\u201351.","journal-title":"JAMA Psychiat"},{"key":"1456_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2023.107740","volume":"144","author":"K Petrilli","year":"2023","unstructured":"Petrilli K, Hines L, Adams S, Morgan CJ, Curran HV, Freeman TP. High potency cannabis use, mental health symptoms and cannabis dependence: triangulating the evidence. Addict Behav. 2023;144:107740.","journal-title":"Addict Behav"},{"issue":"14","key":"1456_CR20","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1017\/S0033291719002460","volume":"50","author":"S Craft","year":"2020","unstructured":"Craft S, Winstock A, Ferris J, Mackie C, Lynskey MT, Freeman TP. Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55,000 people who use cannabis and associations with severity of cannabis dependence. Psychol Med. 2020;50(14):2364\u201373.","journal-title":"Psychol Med"},{"key":"1456_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103381","volume":"99","author":"B Fischer","year":"2022","unstructured":"Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, et al. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. Int J Drug Policy. 2022;99:103381.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1456_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/add.14174","volume":"113","author":"NC Salloum","year":"2018","unstructured":"Salloum NC, Krauss MJ, Agrawal A, Bierut LJ, Grucza RA. A reciprocal effects analysis of cannabis use and perceptions of risk. Addiction. 2018;113(6):1077\u201385.","journal-title":"Addiction"},{"key":"1456_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-020-00397-w","volume":"17","author":"C Leos-Toro","year":"2020","unstructured":"Leos-Toro C, Fong GT, Meyer SB, Hammond D. Cannabis health knowledge and risk perceptions among Canadian youth and young adults. Harm Reduct J. 2020;17:1\u20133.","journal-title":"Harm Reduct J"},{"key":"1456_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110915","volume":"251","author":"AR Florimbio","year":"2023","unstructured":"Florimbio AR, Walton MA, Coughlin LN, Lin LA, Bonar EE. Perceived risk of harm for different methods of cannabis consumption: a brief report. Drug Alcohol Depend. 2023;251:110915.","journal-title":"Drug Alcohol Depend"},{"key":"1456_CR25","unstructured":"Couch, D. Left behind: The scale of illegal cannabis use for medicinal intent in the UK. 2020. https:\/\/irp-cdn.multiscreensite.com\/51b75a3b\/files\/uploaded\/Centre%20for%20Medicinal%20Cannabis%20%7C%20YouGov%20MC%20Paper.pdf. Accessed 5 March 2025."},{"issue":"9","key":"1456_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038687","volume":"10","author":"D Nutt","year":"2020","unstructured":"Nutt D, Bazire S, Phillips LD, Schlag AK. So near yet so far: why won\u2019t the UK prescribe medical cannabis? BMJ Open. 2020;10(9):e038687.","journal-title":"BMJ Open"},{"issue":"8","key":"1456_CR27","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1111\/add.15371","volume":"116","author":"H Charles","year":"2021","unstructured":"Charles H, Heron J, Hickman M, Brown J, Hines L. Testing the validity of national drug surveys: comparison between a general population cohort and household surveys. Addiction. 2021;116(8):2076\u201383.","journal-title":"Addiction"},{"key":"1456_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1279123","volume":"14","author":"B Ciesluk","year":"2021","unstructured":"Ciesluk B, Erridge S, Sodergren MH, Troup LJ. Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users. Front Psychol. 2021;14:1279123.","journal-title":"Front Psychol"},{"key":"1456_CR29","unstructured":"American Association for Public Opinion Research. Online Panels. 2016. https:\/\/www.aapor.org\/Education-Resources\/Election-Polling-Resources\/Online-Panels.aspx. Accessed March 6, 2025."},{"key":"1456_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102698","volume":"77","author":"D Hammond","year":"2020","unstructured":"Hammond D, Goodman S, Wadsworth E, Rynard V, Boudreau C, Hall W. Evaluating the impacts of cannabis legalization: the International Cannabis Policy Study. Int J Drug Policy. 2020;77:102698.","journal-title":"Int J Drug Policy"},{"key":"1456_CR31","unstructured":"Iraniparast M, Rynard V, Burkhalter R, Corsetti D, Hammond D. International Cannabis Policy Study Technical Report\u2014Wave 6 (2023). University of Waterloo; Waterloo, ON, Canada. 2023. http:\/\/cannabisproject.ca\/methods\/"},{"key":"1456_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/can.2016.0022","volume":"1","author":"MO Bonn-Miller","year":"2016","unstructured":"Bonn-Miller MO, Heinz AJ, Smith EV, Bruno R, Adamson S. Preliminary development of a brief cannabis use disorder screening tool: the Cannabis Use Disorder Identification Test Short-Form. Cannabis Cannabinoid Res. 2016;1:252\u201361. https:\/\/doi.org\/10.1089\/can.2016.0022.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1456_CR33","unstructured":"Office for National Statistics. Estimates of the population for the UK, England, Wales, Scotland and Northern Ireland: mid-2021. 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2021. Accessed 5 March 2025."},{"key":"1456_CR34","unstructured":"Office for National Statistics. Census 2021, Census 2021 estimates that classify usual residents in England and Wales by ethnic group, by sex, and by age. Release date March 28, 2023. Customised. 2023. https:\/\/www.ons.gov.uk\/datasets\/RM032\/editions\/2021\/versions\/1. Accessed 5 March 2025."},{"key":"1456_CR35","unstructured":"Office for National Statistics. Census 2021, England and Wales, Age (B) (61 categories) and Highest level of qualification (8 categories). 2023. https:\/\/www.ons.gov.uk\/filters\/f2981ca9-ec38-4302-8ace-f2e1b2f36699\/dimensions. Accessed 5 March 2025"},{"key":"1456_CR36","unstructured":"Office for National Statistics. Drug misuse in England and Wales: year ending March 2023. Appendix table 3.04. 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/datasets\/drugmisuseinenglandandwalesappendixtable. Accessed 5 March 2025"},{"key":"1456_CR37","unstructured":"National Records of Scotland. Scotland\u2019s Census 2011, DC2101SC\u2014Ethnic group by sex by age. 2012. https:\/\/www.scotlandscensus.gov.uk\/webapi\/jsf\/tableView\/tableView.xhtml. Accessed 5 March 2025"},{"key":"1456_CR38","unstructured":"National Records of Scotland. Scotland\u2019s Census 2011, DC5102SC. Highest level of qualification by sex and age, All people aged 16 and over. 2012. https:\/\/www.scotlandscensus.gov.uk\/search-the-census#\/. Accessed 5 March 2025"},{"key":"1456_CR39","unstructured":"Scottish Government. Scottish Health Survey 2021. Supplementary table L9: Taken Cannabis in the last 12 months by age, 2021. 2021. https:\/\/www.gov.scot\/publications\/scottish-health-survey-2021-supplementary-tables. Accessed 5 March 2025"},{"key":"1456_CR40","unstructured":"Northern Ireland Statistics and Research Agency. Census 2021, MS-B01\u2014Ethnic group by age\u201486 categories. 2021. https:\/\/build.nisra.gov.uk\/en\/custom\/data?d=PEOPLE&v=ETHNIC_GROUP_INTERMEDIATE&v=AGE_SYOA_85. Accessed 5 March 2025"},{"key":"1456_CR41","unstructured":"Northern Ireland Statistics and Research Agency. Census 2021, Qualifications (Highest level) by age\u201486 categories. 2021. https:\/\/build.nisra.gov.uk\/en\/custom\/variables?d=PEOPLE&v=HIGHEST_QUALIFICATION&v=AGE_SYOA_85. Accessed 5 March 2025"},{"key":"1456_CR42","unstructured":"European Union Drugs Agency. European Drug Report 2025: Trends and Developments. Cannabis\u2014the current situation in Europe. 2025. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/cannabis_en#0-level-4. Accessed 16 December 2025."},{"issue":"8","key":"1456_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21080986","volume":"21","author":"NG Choi","year":"2024","unstructured":"Choi NG, Marti CN, Choi BY. Associations between cannabis consumption methods and cannabis risk perception. Int J Environ Res Public Health. 2024;21(8):986. https:\/\/doi.org\/10.3390\/ijerph21080986.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1456_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/10826084.2017.1343353","volume":"53","author":"KC Giombi","year":"2018","unstructured":"Giombi KC, Kosa KM, Rains C, Cates SC. Consumers\u2019 perceptions of edible marijuana products for recreational use: likes, dislikes, and reasons for use. Subst Use Misuse. 2018;53(4):541\u20137.","journal-title":"Subst Use Misuse"},{"key":"1456_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107660","volume":"205","author":"BA Reboussin","year":"2019","unstructured":"Reboussin BA, Wagoner KG, Sutfin EL, Suerken C, Ross JC, Egan KL, et al. Trends in marijuana edible consumption and perceptions of harm in a cohort of young adults. Drug Alcohol Depend. 2019;205:107660.","journal-title":"Drug Alcohol Depend"},{"key":"1456_CR46","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2016.op.0035.1611","author":"DG Barrus","year":"2016","unstructured":"Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, et al. Tasty THC: promises and challenges of cannabis edibles. RTI Press Methods Rep. 2016. https:\/\/doi.org\/10.3768\/rtipress.2016.op.0035.1611.","journal-title":"RTI Press Methods Rep"},{"key":"1456_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108873","volume":"226","author":"NS Levy","year":"2021","unstructured":"Levy NS, Mauro PM, Mauro CM, Segura LE, Martins SS. Joint perceptions of the risk and availability of cannabis in the United States, 2002\u20132018. Drug Alcohol Depend. 2021;226:108873.","journal-title":"Drug Alcohol Depend"},{"key":"1456_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2022.107336","volume":"131","author":"N Nguyen","year":"2022","unstructured":"Nguyen N, Wong M, Delucchi K, Halpern-Felsher B. Adolescents\u2019 and young adults\u2019 perceptions of risks and benefits differ by type of cannabis products. Addict Behav. 2022;131:107336.","journal-title":"Addict Behav"},{"key":"1456_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/add.14883","volume":"115","author":"LR Pacek","year":"2020","unstructured":"Pacek LR, Weinberger AH, Zhu J, Goodwin RD. Rapid increase in the prevalence of cannabis use among people with depression in the United States, 2005\u20132017: The role of differentially changing risk perceptions. Addiction. 2020;115:935\u201343.","journal-title":"Addiction"},{"key":"1456_CR50","unstructured":"Curaleaf. Curaleaf Clinic: FAQs. 2025. https:\/\/curaleafclinic.com\/faqs\/. Accessed 18 June 2025."},{"key":"1456_CR51","doi-asserted-by":"publisher","unstructured":"Gardner M, Proctor K, Old M, Cozier G, Scott J, Sutcliffe O, et al. Identification and quantification of THC and the synthetic cannabinoid MDMB-4en-PINACA in edible products seized by UK police in 2024. ChemRxiv [Preprint]. 2025. https:\/\/doi.org\/10.26434\/chemrxiv-2025-3sk0t","DOI":"10.26434\/chemrxiv-2025-3sk0t"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01456-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:22:05Z","timestamp":1781220125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01456-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01456-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed by and received ethics clearance through the University of Waterloo (ORE#31330) and the University of Bath (0513-586). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all respondents and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare. DH has served as a paid Expert Witness on behalf of public health authorities in response to industry legal challenges to cannabis regulations in Canada.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}